Zydus Lifesciences Ltd.

Cadila Healthcare, a global pharmaceutical company, and Zydus Pharmaceuticals (USA, a leading generic pharmaceutical company in the United States, have entered into a settlement and license agreement with Somaxon Pharmaceuticals, and ProCom One to resolve pending patent litigation involving Silenor (Doxepin) 3 mg and 6 mg tablets.

Under the settlement and license agreement, Cadila Healthcare and Zydus Pharmaceuticals (USA), have the right to begin selling a generic version of Silenor 180 days after another party begins selling a generic version of Silenor in the United States under a license from Somaxon, 180 days after a United States court enters a final decision that Somaxon’s patents are not infringed, invalid or unenforceable, or earlier under certain circumstances.

Cadila Healthcare focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.